UniSA Ventures, a tech commercialization unit of the University of South Australia, has secured A$45 million ($31 million) from a group of Chinese investors for an Australia-focused biotechnology fund.
The Chinese investors are based in Nanjing and led by An Lufan, executive director of D&R Pharmaceuticals, one of China’s leading drug development companies. D&R, which operates two R&D centers and three...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.